Latest news with #Quiver
Business Wire
01-07-2025
- Business
- Business Wire
Quiver Bioscience Secures Non-Dilutive Funding to Enhance CNS Genetic Medicine Drug Discovery Platform Capabilities and Advance Powerful AI/ML-Based In Vitro / In Silico Predictor of CNS Drug Safety
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Quiver Bioscience ('Quiver'), a discovery technology and therapeutics company advancing programs for treatment of serious central nervous system (CNS) disorders and chronic pain, today announced receipt of a Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH). The Phase II grant, awarded by the National Institute of Neurological Disease and Stroke (NINDS) is titled ' Safe-OPTION: Optical Physiology To Interrogate Oligonucleotide Neurotoxicity.' It will provide Quiver with $2.15 million over three years to continue development of an integrated platform for improved prediction of safety and tolerability of CNS-targeted antisense oligonucleotide (ASO) therapeutics. ASO therapeutics are increasingly being developed for the treatment of neurological conditions, as they offer precision regulation of disease target activity. Despite demonstrated clinical success of ASOs for neurological disorders, ASO drug development in this area faces the challenge of ensuring that candidates avoid modality-specific neurotoxicity, requiring lengthy preclinical safety studies in several animal species. Incorporating improved earlier predictors of ASO-induced acute and delayed onset neurotoxicity will allow for more efficient ASO drug development. Quiver has built an exceptional drug discovery platform which combines disease relevant human neuronal models, all-optical electrophysiology-based functional readouts, and AI/ML-enabled analytics to provide unique insights into neurological disorders and accelerate drug development. With the new SBIR funding, Quiver will further augment their existing ASO drug development capabilities by applying their platform to better prediction of ASO CNS toxicity using a combination of machine learning (ML)-based in silico ASO design tools and a series of all-optical electrophysiology platform-based in vitro neuronal functional assays, benchmarking their predictive algorithm with empirical data from rodent studies. This enhanced platform will accelerate the ASO drug development process by rapidly identifying lead molecules with better probability of clinical success while also reducing costs and time associated with preclinical animal studies. Quiver's objectives in this newly funded project are aptly aligned with the FDA's push towards replacement of preclinical animal safety studies with New Approach Methodologies (NAMs), including in vitro human cellular systems and artificial intelligence (AI) / machine learning (ML)-based in silico models. While animal models have been historically valuable in understanding disease biology and facilitating drug development, they do have limitations including the fact that animal studies are not scalable, and they can be prohibitively expensive and time consuming. In addition, due to species-specific variations in biology, animal models may not accurately predict performance of a drug compound in humans. Advanced human cellular models have transformed the field of drug discovery in neurological disorders by allowing for the study of biological mechanisms and evaluation of drug targets in live functional neurons carrying the same genetic basis as neurons in human subjects affected by the disease. Quiver's platform uniquely probes neuronal biology at a scale that is not possible with alternative technologies and fills a gap in the ability to directly target fundamental neurophysiological mechanisms for therapeutic discovery. With the added capabilities built partly with this new funding, Quiver now addresses the outstanding challenges associated with predicting and mitigating neurotoxicity related to ASO therapeutics. Quiver has already leveraged their unique ASO design and in vitro screening platform to advance internal precision gene-targeted therapy programs including their lead asset, an ASO candidate targeting the genetically and clinically validated pain target Na v 1.7, a voltage gated sodium channel implicated in several neuropathic pain disorders. In addition to NIH SBIR awards, Quiver has recently received grant support from key patient advocacy and research groups who are focused on advancing precision medicines for neurological disorders. These include grants from the Dup15q Alliance, the FRAXA Research Foundation, and the KCNT1 Epilepsy Foundation in partnership with CURE Epilepsy and are all intended to support Quiver's drug discovery programs related to each of the three CNS disorders (Dup15q syndrome, Fragile X syndrome (FXS), and KCNT1-related epilepsy, respectively). Quiver recently announced a FXS-focused research collaboration with QurAlis, which will be partially supported by the new FRAXA Research Foundation grant. These partnerships are instrumental to Quiver's mission to accelerate transformative therapeutic discovery for both rare and common disorders of the CNS. About Quiver Bioscience Quiver Bioscience is a technology-driven company established to create transformational medicines for the brain while simultaneously uncovering new biology and novel, effective drug targets. Using advanced single-cell imaging and multi-omics, we are building the world's most information-rich neuronal insight map via our "Genomic Positioning System." Our approach integrates cutting-edge scalable human models, state-of-the-art technology and proprietary engineering, and learning and surrogate AI/ML models to identify novel therapeutic targets and the best candidate molecules to deliver new and meaningful therapeutics to patients. For more information, including partnerships and publications describing application of Quiver's GPS to drug discovery, visit or follow us on LinkedIn.
New York Post
25-06-2025
- Entertainment
- New York Post
‘Cobra Kai' actors reveal BTS footage the day of shocking bite altercation
The fun before the bite. 'Cobra Kai' actors Martin Kove and Alicia Hannah-Kim shared behind-the-scenes footage on social media Sunday from the fan convention where Hannah-Kim, 37, accused Kove, 78, of biting her arm. 12 Martin Kove attends Netflix's 'Cobra Kai' series finale premiere in Feb. 2025. Getty Images for Netflix Advertisement 12 Alicia Hannah-Kim attends the 'Cobra Kai' series finale premiere in Feb. 2025. Variety via Getty Images Kove posted an Instagram clip of himself signing a fan's 'Cobra Kai' poster at the Washington State Summer Con in Puyallup seemingly before the incident occurred. 'It's forever. Cobra Kai never dies,' Kove captioned the video, which was played to the song 'Quiver' from the show's soundtrack. Advertisement 12 Martin Kove at Washington State Summer Con. martinkove/Instagram 12 Martin Kove signing a fan's 'Cobra Kai' poster. martinkove/Instagram Hannah-Kim, for her part, shared two clips from her experience at the fan convention seemingly before things went awry. In the first video, the actress filmed herself at the airport with her luggage before the clip transitioned to her at the convention with a dog in her backpack. Advertisement 'Is this what standing on business means??' Hannah-Kim wrote in her caption. 12 Alicia Hannah-Kim at the airport before the fan convention. thealiciahannah/Instagram 12 Alicia Hannah-Kim at the fan convention. thealiciahannah/Instagram In the second video, Hannah-Kim and some of her co-stars including Rayna Valladingham and Tanner Buchanan excitedly opened Labubu toys from PopMart. The caption read, 'office party was 🤸🏻♀️.' Advertisement 12 Alicia Hannah-Kim with her co-stars at the fan convention. thealiciahannah/Instagram At some point during the convention, Hannah-Kim accused Kove of biting her arm, which reportedly led to Kove being thrown out of the event. According to an informational police report obtained by People, Hannah-Kim claimed the alleged attack happened when she tapped Kove on the shoulder to greet him at their cast booth. 12 Martin Kove attends the '1923' Season 2 premiere in Los Angeles. Getty Images for Paramount+ 'Martin Kove suddenly grabbed her arm and bit her upper arm so hard it nearly drew blood, and she yelled out in pain,' the documents read. 'Once Martin Kove finished biting her arm, he grabbed her arm again and began kissing it where he had bit her.' In bodycam footage, Hannah-Kim and a police officer ripped into Kove for the biting outside the convention center. 'You have left a mark on my body, which in your 80-year-old brain, you think is 'play,'' Hannah-Kim told Kove. 12 Alicia Hannah-Kim seen talking to a police officer about the biting incident. Puyallup Police Dept. Advertisement The Korean-Australian actress also asked the 'Karate Kid' alum if he was 'raised in a ditch,' before she had the officer document the bit mark and stated that she wanted the incident to be 'on his record.' 12 Alicia Hannah-Kim shows a cop the bite mark from Martin Kove. Puyallup Police Dept. Kove, who apologized to Hannah-Kim for getting 'angry,' was informed by the officer that his co-star wasn't pressing charges, but that she wanted the incident documented so it 'doesn't happen again.' 12 Alicia Hannah-Kim attends the Gold House 4th Annual Gold Gala in May 2025. FilmMagic Advertisement The 'DWTS' alum gave a full apology for the incident in a statement obtained by TMZ. 'I deeply regret and apologize for my actions regarding the incident with Alicia, a genuinely kind and wonderful person who didn't deserve to be put in this position,' Kove stated. 12 Martin Kove in 'Cobra Kai.' Netflix 'I've always respected her and considered her a highly professional and talented co-worker on 'Cobra Kai,'' he added. 'I was being playful in the moment but went too far and there is absolutely no excuse for my behavior.' Advertisement 'Cobra Kai,' a sequel to the first three 'Karate Kid' films, ran for six seasons from 2018 to 2025.
Business Wire
16-06-2025
- Business
- Business Wire
Quiver Bioscience Appoints Graham Dempsey, PhD as Chief Executive Officer to Lead Scaling of AI-Driven CNS Platform and Advance Lead Program into the Clinic
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Quiver Bioscience ('Quiver'), a discovery technology and therapeutics company advancing programs for treatment of serious central nervous system (CNS) disorders and chronic pain, announced the appointment of co-founder Graham Dempsey, PhD as Chief Executive Officer. Dr. Dempsey assumes the CEO role after more than a decade of scientific and operational leadership at Quiver, most recently serving as Quiver's Chief Scientific Officer, directing the planning and execution of all scientific, medical, engineering and AI/machine learning activities at the company. This appointment comes as Quiver aims to advance its lead program into the clinic, an antisense oligonucleotide (ASO) targeting Na v 1.7 for the treatment of chronic pain, while scaling its CNS-focused AI-driven drug discovery platform to accelerate a portfolio of therapeutic programs. Paul Roma, Quiver co-founder and interim CEO will transition to Chairman of the Board of Directors. 'We're excited by the potential of our genetic medicine strategy and platform to unlock this important target towards creating a transformative product for patients suffering from chronic neuropathic pain," said Dr. Dempsey Share Dr. Dempsey has successfully led the development and rapid evolution of the company's technology platforms since the company's inception, as well as its first small molecule and antisense oligonucleotide therapeutic programs, resulting in several foundational patents and peer-reviewed publications. He has also led more than a dozen pharma collaborations and the execution of several grants from non-dilutive funding sources such as the NIH SBIR Programs and CNS Foundations. Dr. Dempsey holds a B.A. in biochemistry (Roy and Diana Vagelos Scholar) and biophysics from the University of Pennsylvania and a Ph.D. in biophysics from Harvard Medical School, where he co-invented novel fluorescence-based imaging platforms for investigating biological systems and was part of the team that developed the super-resolution imaging technique called stochastic optical reconstruction microscopy (STORM) that was subsequently commercialized by Nikon Instruments. Dr. Dempsey serves on the Scientific Advisory Board of the Dan Lewis Foundation for Brain Regeneration Research and the editorial board of Molecular Therapy Nucleic Acids. Under Dr. Dempsey's leadership, Quiver will advance their lead asset, an ASO targeting the genetically validated pain target Na v 1.7, a voltage gated sodium channel implicated in several neuropathic pain disorders, through IND and early clinical studies. 'Despite the longstanding promise of Nav1.7 as a target for pain, it has remained elusive for drug developers. We're excited by the potential of our genetic medicine strategy and platform to unlock this important target towards creating a transformative product for patients suffering from chronic neuropathic pain,' said Dr. Dempsey. Quiver's Na v 1.7 ASO is expected to deliver durable relief for chronic pain while overcoming limitations of other Na v -targeted small molecules currently under development and recently approved. Quiver's strong data package demonstrates the efficacy of Na v 1.7 ASOs in rescuing pain phenotypes in in vitro and in vivo models with a favorable CNS tolerability profile. The ASO program is approaching development candidate selection in 2025 and is expected to begin critical IND enabling studies shortly thereafter. Quiver is also scaling their human-centric AI-driven novel CNS drug discovery platform with in silico models of target, efficacy and toxicity prediction, and is further bolstering a pipeline of fast-follower programs in pain, neurodevelopmental disorders, and other diseases of the CNS including the advancement of its UBE3A -targeting ASO for the neurodevelopmental disorder, chromosome 15q duplication syndrome (Dup15q) to IND. The company will be attending the BIO International Convention in Boston this week to showcase their programs and platform. About Quiver Bioscience Quiver Bioscience is a technology-driven company established to create transformational medicines for the brain while simultaneously uncovering new biology and novel, effective drug targets. Using advanced single-cell imaging and multi-omics, we are building the world's most information-rich neuronal insight map via our "Genomic Positioning System." Our approach integrates cutting-edge scalable human models, state-of-the-art technology and proprietary engineering, and learning and surrogate AI/ML models to identify novel therapeutic targets and the best candidate molecules to deliver new and meaningful therapeutics to patients. For more information, including partnerships and publications describing application of Quiver's GPS to drug discovery, visit or follow us on LinkedIn.
Business Wire
15-05-2025
- Business
- Business Wire
Quiver Bioscience and QurAlis Announce Research Collaboration to Advance Novel Therapeutic Approach for Fragile X Syndrome
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Quiver Bioscience ('Quiver') and QurAlis Corporation ('QurAlis'), today announced that the companies have entered into a research collaboration to advance a novel gene-targeted therapeutic approach for the treatment of Fragile X syndrome (FXS). The goal of the collaboration is to combine Quiver's unique 'Genomic Positioning System' (GPS) drug discovery platform with QurAlis' expertise in developing next-generation precision medicines for neurodegenerative and neurological diseases to build a foundational data package in support of advancing a potentially transformative therapeutic for FXS. Quiver's GPS platform integrates unique-in-world, scalable, human neuronal electrophysiology data (the 'language' of the brain) with artificial intelligence and machine learning (AI/ML) to drive novel insights into disease biology and enable optimized drug discovery. Quiver has successfully applied its GPS approach to a variety of central nervous system (CNS) disorders and recently published modeling and drug discovery efforts in FXS. 'Our platform technology is uniquely suited to improving understanding of the molecular and cellular basis of neurogenetic disorders such as FXS. We are excited to embark on this partnership with QurAlis which aspires to bring about groundbreaking therapies for the FXS community,' said Graham Dempsey, Ph.D., co-founder and CEO of Quiver Bioscience. 'FXS is a devastating neurodevelopmental disease. It is the leading inherited form of intellectual disability and known cause of autism for which there are no disease-modifying therapies,' said Kasper Roet, Ph.D., CEO and co-founder of QurAlis. 'We look forward to this research collaboration with Quiver. The combination of enabling technologies and drug development experience built through this partnership holds great promise for progressing novel therapeutics for FXS, for which there exists a significant unmet medical need.' FXS, the leading genetic form of intellectual disability and autism spectrum disorder, is caused by loss of the FMR1 encoded protein Fragile X Messenger Ribonucleoprotein (FMRP). It currently affects approximately 87,000 individuals in the U.S. alone – occurring at an incidence of 1 in 4,000 males and 1 in 6,000 females. In addition to intellectual disability, FXS symptoms include delays in development, seizures, speech difficulties, hyperactivity and attention deficit, severe anxiety, and others. There are no disease-modifying therapies currently available for FXS. Destum Partners acted as transaction advisor to Quiver Bioscience. About Quiver Bioscience Quiver Bioscience is a technology-driven company established to create transformational medicines for the brain while simultaneously uncovering new biology and novel, effective drug targets. Using advanced single-cell imaging and multi-omics, we are building the world's most information-rich neuronal insight map via our "Genomic Positioning System." Our approach integrates cutting-edge scalable human models, state-of-the-art technology and proprietary engineering, and learning and surrogate AI/ML models to identify novel therapeutic targets and the best candidate molecules to deliver new and meaningful therapeutics to patients. For information, including additional publications describing application of Quiver's GPS to drug discovery, visit or follow us on LinkedIn. About QurAlis Corporation At QurAlis, we are neuro pioneers on a quest to cure, boldly seeking to translate scientific breakthroughs into powerful precision medicines. We work collaboratively with a relentless pursuit of knowledge, precise attention to craft, and compassion to discover and develop medicines that have the potential to transform the lives of people living with neurodegenerative and neurological diseases. QurAlis is the leader in development of precision therapies for amyotrophic lateral sclerosis (ALS). In addition to ALS, QurAlis is advancing a robust precision medicine pipeline to bring effective disease-modifying therapeutics to patients suffering from severe diseases defined by genetics and clinical biomarkers. For more information, please visit or follow us on X @QurAlisCo or LinkedIn.
